Hyperthermia in soft tissue sarcoma
- 332 Downloads
Patients with high-risk soft tissue sarcomas (STS)–FNCLCC grade 2–3, size >5 cm, deep to the fascia—are at risk for developing local recurrence and distant metastasis despite surgical tumor resection. Therefore, the management of high–risk STS requires a multidisciplinary approach. Besides surgery, radiotherapy, and chemotherapy, regional hyperthermia (RHT) has the potential to become the fourth standard treatment modality for the treatment of these patients. RHT means non-invasive selective heating of the tumor area to temperatures within the range of 40–43°C for 60 min by the use of an electromagnetic heating device. Thereby RHT is always applied in addition to radiotherapy or chemotherapy or both but is not effective as a single treatment. Beside direct cytotoxicity, RHT in combination with chemotherapy enhances the drug cytotoxicity mainly by increased chemical reaction and intratumoral drug accumulation. For the neoadjuvant setting, RHT in combination with a doxorubicin- and ifosfamide-based chemotherapy has been shown to dramatically improve the tumor response rate but also prevents from early disease progression as compared to chemotherapy alone. The addition of RHT to a multimodal treatment of high-risk STS consisting of surgery, radiotherapy, and chemotherapy either in the neoadjuvant setting but also after incomplete or marginal tumor resection has been shown to significantly improve local recurrence- and disease-free survival. Based on these results and in conjunction with the low RHT-related toxicity, RHT combined with preoperative or postoperative chemotherapy should be considered as an additional standard treatment option for the multidisciplinary treatment of locally advanced high-grade STS.
KeywordsSoft Tissue Sarcoma Ifosfamide Soft Tissue Sarcoma Thermal Enhancement Whole Body Hyperthermia
L Lindner: consulting fees from Medtherm and travel support from PharmaMar; R Issels: consulting fees and travel support from Novartis, Amgen, PharmaMar and MedTherm.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 9.Dahl O. Interaction of heat and drugs in vitro and in vivo. In: Thermoradiotherapy and thermochemotherapy Volume 1. Edited by Seegenschmiedt MH, Fessenden P, Vernon CC. Berlin: Springer; 1995:103–121.Google Scholar
- 13.Noessner E, Gastpar R, Milani V, et al. Tumor-derived heat shock protein 70-peptide complexes are cross-presented by human dendritic cells. J Immunol 2002, 169:5425–5432.Google Scholar
- 16.Jolesch A, Elmer K, Bendz H, et al. Hsp70, a messenger from hyperthermia for the immune system. Eur J Cell Biol 2011, in press.Google Scholar
- 21.Issels RD, Prenninger SW, Nagele A, et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol 1991, 8:1818–1829.Google Scholar
- 23.Issels RD, Abdel-Rahman S, Wendtner CM, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk soft tissue sarcomas (HR-STS) of adults: long-term results of a phase II study. Eur J Cancer 2001, 37:1599–1608.CrossRefPubMedGoogle Scholar
- 24.Wendtner CM, Abdel-Rahman S, Baumert J, et al. Treatment of primary, recurrent or inadequately resected high-risk soft tissue sarcomas (HR-STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001, 37:1609–1616.CrossRefPubMedGoogle Scholar
- 27.Issels RD, Lindner LH, Laubender R, et al. Improvement of local progression (LPFS) and disease-free survival (DFS) by regional hyperthermia (RHT) combined with neoadjuvant chemotherapy in non-extremity (NE) high-risk soft tissue sarcoma (HR-STS) with complete (R0/R1) surgical resection [abstract 897755]. Presented at the CTOS 16th Annual Meeting. Paris, France; November 11–13, 2010.Google Scholar
- 28.Nickenig C, Buecklein V, Lindner LH, et al. Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated nonresponders with locally advanced high-risk soft tissue sarcoma (HR-STS). (ASCO abstract 10581). J Clin Oncol 2009;27:15s.CrossRefGoogle Scholar